Avicanna Inc. Announces Auditor Transition

TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (hereafter referred to as 'Avicanna' or the 'Company'), a pioneering biopharmaceutical firm in the cannabinoid space, has publicized a significant alteration in its corporate structure with the change of its auditing partner.

Introduction of New Auditors

Avicanna, known by its stock tickers AVCN on the TSX and AVCNF on the OTC markets, and also traded under the symbol 0NN in Frankfurt, has revealed it is transitioning from its previous auditor, Kingston Ross Pasnak LLP, in a move to align with the Company's evolving business requirements. The exact reasons behind the change were not disclosed, but such changes are not uncommon in the corporate world and may reflect strategic business decisions.

Company’s Overview and Business Focus

Specializing in the research, development, and commercialization of plant-derived cannabinoid-based products, Avicanna has established itself as a leader in the biopharmaceutical field. The company leverages natural compounds and boasts a focus on scientific rigor in its product development processes.

Impact of Auditor Change

The announcement of the auditor change is a managerial decision that is of interest to shareholders and potential investors. It is essential to track such changes as they can sometimes be indicative of a company’s internal restructuring or a shift in business strategy.

biopharmaceutical, auditors, cannabinoid